FDA tells Life Enthusiast Co-op its three eye products sold online are unapproved new drugs.
What happened
FDA reviewed the company's website at life-enthusiast.com in May 2025 and found "Amazing Colyrio," "Fulvic Eyes," and "MSM Gold Drops" offered for sale with claims to treat eye irritation, dry eyes, eye strain, infections, and joint problems. FDA said these claims make the products drugs, and that they are not generally recognized as safe and effective for those uses, so they are unapproved new drugs under U.S. law. FDA also said "MSM Gold Drops" is not a dietary supplement because it is meant for topical use, not swallowing.
What FDA found
The website claims these products treat eye irritation, dry eyes, infections, and joint problems, which makes them drugs under the law.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)The products are not generally recognized as safe and effective for the uses claimed, so they are "new drugs."
Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)No FDA-approved application is in effect for these products, so selling them breaks the new drug approval requirement.
Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)"MSM Gold Drops" is marketed as a dietary supplement, but a supplement must be intended for swallowing and this one is for topical use.
Section 201(ff)(2)(A)(i) of the FD&C Act, 21 U.S.C. 321(ff)(2)(A)(i)Eye products carry extra risk because putting a product directly in the eye bypasses some of the body's natural defenses.
What FDA wants
FDA asks the company to write back within fifteen working days describing the steps taken to fix the violations and prevent them from happening again, with supporting documents. If the company believes it is not in violation, it should explain why and send supporting information.
Who should pay attention
- online retailers and health websites selling eye drops or eye-care products
- brands whose eye products carry treatment or structure/function claims
- marketers and copywriters writing product claims for eye-care items
This is a summary. Read the original letter on fda.gov.